ROSEN, NATIONALLY RECOGNIZED INVESTOR COUNSEL, Encourages Integer Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – ITGR GlobeNewswire December 17, 2025 NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common […]

Recently,Meizhou in Guangdong, known as the “World Capital of the Hakka”, welcomed a globally watched event, the Seventh World Hakka Entrepreneurs Convention. At this gathering that drew the attention of Hakka entrepreneurs worldwide, Guangdong Jiaying Pharmaceutical Co., Ltd. made a brilliant appearance with its star products, including Double-ingredient Throat Wind Relief Powder, Solid Essence Ginseng

Churchill Capital Corp XI (the “Company”) announced the pricing of its upsized initial public offering of 36,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market (“Nasdaq”) under the symbol “CCXIU” commencing today. Each unit consists of one Class A ordinary share of the Company and one-tenth of one

(NASDAQ:HCM),(LSE – AIM:HCM),(HKSE:0013), — First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the initiation of its global Phase

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors GlobeNewswire December 17, 2025 — First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE)

Vancouver, BC / YOLOWIRE / December 16, 2025 / Silver Viper Minerals Corp. (TSXV: VIPR; OTCQB: VIPRF) (the "Company") (the "Company") is pleased to announce that it has engaged IMPAQ Capital Inc. ("IMPAQ"), an independent service provider, to deliver investor relations services. Based in Montréal, Québec, IMPAQ specializes in tailored outreach programs that connect companies

(NASDAQ:TLX), SAN FRANCISCO, Dec. 16, 2025 (GLOBE NEWSWIRE) — National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026. The lawsuit follows a

21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) GlobeNewswire December 16, 2025 SAN FRANCISCO, Dec. 16, 2025 (GLOBE NEWSWIRE)

(NASDAQ:RZLT), SAN FRANCISCO, Dec. 16, 2025 (GLOBE NEWSWIRE) — On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much as 90% during intraday trading after the company revealed the failure of its Phase 3 sunRIZE trial for ersodetug (“erso”). The company has billed this drug as

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure — Hagens Berman Investigating RZLT Investors with Losses Encouraged to Contact the Firm GlobeNewswire December 16, 2025 SAN FRANCISCO, Dec. 16, 2025 (GLOBE NEWSWIRE) — On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) saw the price of their shares crater as much